Comparison of Five Anti-SARS-CoV-2 Antibody Assays Across Three Doses of BNT162b2 Reveals Insufficient Standardization of SARS-CoV-2 Serology

Perkmann, Thomas; Mucher, Patrick; Ösze, Darlene; Müller, Antonia; Perkmann-Nagele, Nicole; Köller, Thomas; Radakovics, Astrid; Flieder, Ines; Repl, Manuela; Marculescu, Rodrig; Wolzt, Michael; Wagner, Oswald; Binder, Christoph J.; Haslacher, Helmuth

doi:10.2139/ssrn.4236131

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Before the start of the 2021-2022 National Basketball Association (NBA) season, players and team staff underwent assessment of their SARS-CoV-2 antibody titers using the DiaSorin LIAISON SARS-CoV-2 TrimericS IgG assay (the "TrimericS Assay") which was developed to measure antibodies against the WA-1 spike protein and received FDA emergency use authorization on May 19, 2021 [13]. At the time, the TrimericS assay was chosen for its high correlation to neutralizing antibodies compared to other commercially available platforms [14][15][16][17]. Individuals were included if they met the following criteria: aged 18 and older who voluntarily had their SARS-CoV-2 antibody titers measured using the TrimericS Assay from September 12, 2021 through December 31, 2021 and completed their primary SARS-CoV-2 vaccine series by time of antibody testing.…”

Section: Methodsmentioning

confidence: 99%

Low Antibody Titers Demonstrate Significantly Increased Rate of SARS-CoV-2 Infection in a Highly Vaccinated Population from the National Basketball Association

Tai

Haviland

Kissler

et al. 2023

Preprint

View full text Add to dashboard Cite

SARS-CoV-2 antibody titers may serve as a correlate for immunity and could inform optimal booster timing. The relationship between antibody titer and protection from infection was evaluated in 2,323 vaccinated individuals from the National Basketball Association who had antibody levels measured from 9/12/2021 to 12/31/2021. Cox-proportional hazards models were used to estimate risk of infection within 90-days of serologic testing by titer level (<250, 250-800, and >800 AU/mL) and individuals were censored on date of booster receipt. The cohort was 78.2% male, 68.1% aged ≤ 40 years, and 56.4% vaccinated (primary series) with the Pfizer-BioNTech mRNA vaccine. Among the 2,248 individuals not yet boosted at testing, those with titers <250 AU/mL (adj HR: 2.4; 95% CI: 1.5, 3.7) and 250-800 800 AU/mL (adj HR: 1.5; 95% CI: 0.98, 2.4) had greater infection risk compared to those with titers >800 AU/mL. Serologic titers could inform individual COVID-19 risk and booster scheduling.

show abstract

Section: Methodsmentioning

confidence: 99%